Is Libre 3 Accurate? What Clinical Data Shows

The FreeStyle Libre 3 is one of the more accurate continuous glucose monitors available today, with clinical trial data showing an overall mean absolute relative difference (MARD) of about 7.8% when compared against laboratory-grade blood glucose measurements. That number means the average sensor reading strays less than 8% from the true value, a level of precision that meets the international threshold for making insulin-dosing decisions without a confirmatory fingerstick. But accuracy in a controlled clinical setting and accuracy on your arm during a workout or at altitude are different conversations, and the clinical data paints a more layered picture than any single number can capture.

What the Pivotal Clinical Trial Found

The accuracy claim for the Libre 3 rests primarily on a controlled study that collected nearly 6,845 paired readings, each matching a sensor glucose value to a venous blood sample analyzed by a YSI reference analyzer, the gold standard for glucose measurement in laboratory settings. Across participants aged six years and older, the overall MARD came in at 7.8%, and about 93.4% of all sensor readings fell within ±20% of the reference value (or within ±20 mg/dL for readings below 80 mg/dL).¹ A separate evaluation described in Clinical Diabetes reported a similar figure, citing an overall MARD of 7.9% against venous blood reference values across a wide glucose range.²

For context, MARD is the standard yardstick used across the glucose monitoring industry. A MARD below 10% is generally considered the benchmark for a system accurate enough to support non-adjunctive use, meaning you can dose insulin based on the sensor reading alone without needing to prick your finger first. At around 7.8–7.9%, the Libre 3 clears that bar with some room to spare.

What a MARD of 7.8% feels like in everyday terms depends on where your glucose sits. If your actual blood glucose is 150 mg/dL, the sensor might read anywhere from roughly 138 to 162 on average. At 80 mg/dL, the sensor might read between about 74 and 86. Those swings are small enough that most treatment decisions stay the same, but they are large enough to notice if you are used to the precision of a well-calibrated blood glucose meter.

How the Libre 3 Stacks Up Against the Dexcom G7

Head-to-head comparisons between the Libre 3 and its main rival, the Dexcom G7, are among the data points prospective users care about most. A controlled study that ran both sensors simultaneously on the same participants found a statistically significant accuracy gap: the Libre 3 posted a MARD of 8.9% compared to 13.6% for the Dexcom G7. About 91.4% of Libre 3 readings fell within ±20 mg/dL or ±20% of the reference, versus 78.6% for the G7.³

The same study noted an interesting pattern in early-wear accuracy. During the first 12 hours after insertion, both sensors performed similarly. After that initial window, the Libre 3’s MARD stayed relatively low at around 10%, while the Dexcom G7’s climbed to about 15.1%. That early-wear convergence matters because many CGM users have learned to distrust their sensor readings on the first day. For the Libre 3, the data suggests the first 12 hours are comparable to the rest of the wear period rather than dramatically worse.³

A study conducted under more extreme conditions—recreational scuba diving with people who have type 1 diabetes—pushed both sensors much harder. Underwater, the Libre 3 registered an overall MARD of 14.2%, while the Dexcom G7 ballooned to 31%. Safety grid analysis showed 97.4% of Libre 3 readings in the no-risk zone compared to 82.1% for the G7. The Libre 3 also performed better at identifying low blood sugar episodes, with a diagnostic odds ratio of roughly 254 versus about 59 for the G7.⁴ Neither sensor, however, achieved accuracy levels that met the MARD threshold for non-adjunctive use during diving. That underscores a broader principle: accuracy benchmarks from controlled clinical studies do not automatically transfer to high-demand real-world scenarios.

How Exercise Affects Sensor Readings

Exercise is one of the situations where CGM users most commonly notice their sensor readings diverging from how they actually feel. Muscles pulling glucose out of the bloodstream, changing blood flow patterns, and sweat can all theoretically interfere with the electrochemical reaction happening at the sensor filament. For the Libre 3, a study examined accuracy during moderate-intensity continuous aerobic exercise in females with type 1 diabetes and found that MARD values ran around 14–15% before exercise and rose to about 17–18% afterward.⁵

Those numbers are higher than the 7.8% from the pivotal trial, but the researchers characterized the accuracy as still “good” and found that exercise itself did not produce a statistically meaningful accuracy hit. The study also examined whether the phase of the menstrual cycle influenced sensor accuracy, a question that has been raised for hormonal effects on interstitial fluid dynamics. The follicular and luteal phases showed nearly identical MARD values, suggesting that hormonal cycling does not introduce meaningful additional error.⁵

Still, a MARD in the mid-teens during and after exercise means that if your actual glucose is 100 mg/dL, the sensor might read as low as 83 or as high as 117. That range is wide enough to influence whether you decide to eat a snack or take a correction dose during a run. Many experienced CGM users learn to rely more on trend arrows than absolute numbers during physical activity, watching whether glucose is falling, stable, or rising rather than fixating on the exact reading.

The Interstitial Lag and What It Means for Fast Changes

All continuous glucose monitors, including the Libre 3, measure glucose in interstitial fluid rather than directly in the blood. Interstitial fluid is the thin layer of liquid surrounding your cells just beneath the skin, and glucose concentration there trails behind blood glucose by a physiological delay, typically on the order of five to fifteen minutes. This lag is not a flaw in the sensor’s engineering so much as an unavoidable consequence of the biology. Glucose has to diffuse from capillaries into the surrounding tissue before the sensor can detect it.

In practice, the lag matters most when your blood sugar is changing quickly. After a meal, blood glucose might spike sharply while the sensor is still reading the lower value from minutes earlier. Conversely, during a fast drop caused by insulin or intense exercise, the sensor reading may stay higher than your actual blood sugar for several minutes. This is a key reason that CGM accuracy studies report worse MARD values during exercise and other dynamic situations compared to steady-state conditions. The sensor itself is not necessarily less accurate; it is just measuring a compartment that is running behind.

The Libre 3 streams readings continuously to a phone via Bluetooth, updating every minute. That real-time streaming is an improvement over the earlier Libre 2, which required a manual scan. The continuous data flow means you get trend information faster, which partially compensates for the interstitial lag since you can see the direction and speed of change even if the absolute number is slightly behind.

Where You Wear It Matters

The Libre 3 is approved for wear on the back of the upper arm, and the pivotal trial data comes from that placement. But many users wonder about alternative locations, whether because they find the arm inconvenient, because they sleep on that side, or because clothing irritates the sensor. A study that tested the Libre system on the upper back and chest in addition to the standard arm site found that back and chest placements achieved accuracy scores of about 97.9% and 98%, respectively, compared against the arm sensor’s readings. Under experimental conditions, the arm sensor was slightly more accurate than both alternatives. All three sites tended to read higher than venous samples during exercise.⁶

The chest and arm sites were the most preferred by participants, while the back had the highest rate of sensor failures, likely due to mechanical stress from lying on it or bumping it against chairs. If you choose an alternative site, keep in mind that the readings may track closely with the arm but are technically off-label, meaning the manufacturer has not validated accuracy for those placements and your clinician may not support the practice.

Compression Lows and Other False Alarms

If you have ever been startled awake by a low glucose alarm in the middle of the night only to do a fingerstick and find your blood sugar is perfectly normal, you have experienced what the CGM community calls a “compression low.” This happens when you lie on the sensor, physically pressing it into your tissue. The pressure reduces blood flow to the area around the sensor filament, causing glucose delivery to that spot to drop temporarily. The sensor faithfully measures the genuinely reduced glucose in its immediate environment, so the reading is technically accurate at the sensor tip. It just does not represent what is happening in the rest of your body.

Compression lows are a known issue across all subcutaneous CGM systems, not a Libre 3-specific flaw. Wearing the sensor on the back of the upper arm, as recommended, helps because most people do not sleep directly on the back of their arm. But side sleepers with the sensor on their sleeping-side arm may still encounter these false dips. The practical fix is simple: if you get a low alarm at night and you were lying on the sensor, sit up, wait five to ten minutes, and check the reading again. If it bounces back, the alarm was a compression artifact.

Low Oxygen and High Altitude

The electrochemical reaction at the heart of most CGM sensors depends on oxygen. Glucose oxidase, the enzyme on the sensor filament, needs oxygen to convert glucose into a measurable electrical signal. That raises a natural question about what happens when oxygen levels are unusually low, whether from high-altitude travel, flying in a pressurized cabin, or certain medical conditions like sleep apnea.

A randomized controlled trial specifically designed to test CGM accuracy under standardized hypoxia conditions acknowledged that while sensor accuracy is well established under normal oxygen levels, very little evidence exists for performance during hypoxia.⁷ This is an active area of research. For the typical user, commercial airline cabins are pressurized to an equivalent altitude of about 6,000 to 8,000 feet, which produces only a mild reduction in blood oxygen. Anecdotal reports from users flying or hiking at moderate altitudes generally do not flag dramatic sensor failures. But if you are planning high-altitude mountaineering or have a condition that chronically lowers your blood oxygen, this is an area where sensor readings deserve extra skepticism and confirmatory fingersticks are prudent.

The scuba diving study cited earlier offers a window into how an extreme environment degrades accuracy. Underwater pressure changes, temperature shifts, and altered perfusion all conspired to push the Libre 3’s MARD from around 8–9% to over 14%. The sensor was still the better performer in that study, but neither it nor its competitor met the standard for insulin dosing without fingerstick confirmation.⁴

Outcomes in Type 2 Diabetes

Most of the clinical accuracy data for the Libre 3 comes from studies involving people with type 1 diabetes, since that population uses CGMs most intensively and requires the highest sensor accuracy for insulin management. But the Libre system has also been studied in people with type 2 diabetes, and the results are worth noting even though they speak more to effectiveness than raw sensor accuracy.

A real-world analysis of people with type 2 diabetes who started using the FreeStyle Libre system found meaningful drops in HbA1c. At six months, a cohort of 774 users saw an average HbA1c reduction of about 0.8 percentage points. By twelve months, a smaller cohort of 207 people maintained a 0.6 percentage point reduction. The largest improvements showed up in people with type 2 diabetes who were not on insulin at all, with a 0.9 percentage point drop at six months.⁸ The interpretation here is that the visibility CGM provides into glucose patterns helps people and their clinicians make better decisions about diet, timing, and medication, even when the clinical use case is less intensive than type 1 management.

This matters because type 2 diabetes accounts for the overwhelming majority of diabetes cases, and the question of whether CGMs are “worth it” for this population is still debated in many healthcare systems. The accuracy of the Libre 3 sensor itself does not change between a type 1 and a type 2 user. The sensor measures interstitial glucose the same way regardless of the underlying disease. What changes is the clinical context in which accuracy matters and the threshold at which a slightly off reading could lead to a harmful decision.

Pediatric Use and Skin Reactions

For parents managing a child’s diabetes, sensor comfort and skin tolerance matter as much as glucose accuracy. A prospective study of children and adolescents with type 1 diabetes in Spain looked at the FreeStyle Libre system over an extended follow-up period. Mild adverse events related to the device were uncommon: skin reactions and discomfort or pain showed small reductions during follow-up of 3.1% and 6.6%, respectively, though those reductions were not statistically significant.⁹

Skin irritation from adhesive is probably the most common non-accuracy complaint across all CGM platforms. Some users develop contact dermatitis from isobornyl acrylate or other adhesive components. Barrier wipes, skin-prep products, or adhesive patches placed under the sensor can mitigate this for most people, though a small number of users find the irritation intolerable enough to stop wearing the device. The Libre 3’s smaller sensor footprint, described as roughly the size of two stacked U.S. pennies, means less adhesive contact area compared to bulkier alternatives, which may help some sensitive-skinned users.²

When to Trust the Number and When to Check

The clinical data consistently shows that the Libre 3 is accurate enough for most day-to-day diabetes management decisions, including insulin dosing, under normal conditions. But the data also consistently shows that accuracy degrades in specific, identifiable situations: rapid glucose changes after meals or during exercise, physical pressure on the sensor, extreme environments like underwater or potentially at high altitude, and the physiological lag inherent in measuring interstitial fluid rather than blood.

A reasonable approach, and one most diabetes educators recommend, is to treat the sensor as your primary source of glucose information but keep a blood glucose meter accessible for moments of doubt. If the sensor reading does not match how you feel, if you are about to make a significant dosing decision during a rapid change, or if you have been lying on the sensor, a fingerstick takes thirty seconds and can either confirm or override the CGM value. The Libre 3 is accurate enough that many users go weeks without ever needing that backup. But carrying the option is cheap insurance, and the clinical data supports exactly that kind of layered trust.